1. Home
  2. BMRN
  3. BMRN Forecast

as of 11-28-2025 12:37pm EST

$55.79
+$0.38
+0.69%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

Frequently Asked Questions

Learn more about our BMRN ML prediction model

What parameters are used to train the BMRN ML model?

Our stocks BMRN ML model is trained using historical data with over 25 parameters, including volume indicators, volatility indicators, momentum indicators, trend indicators, and other technical metrics.

How often is the BMRN ML model updated?

We update our ML model weekly or biweekly (depending on market capitalization) using TensorFlow, typically over the weekend to ensure the most current predictions.

Why might the model accuracy vary?

Our current data provider offers limited historical data, which can impact accuracy. As we continue to gather more data and add additional indicators, we expect the model's accuracy to improve over time.

How can I contribute data to improve accuracy?

We greatly appreciate contributions! Please contact us at info@finquota.com to discuss how you can help improve our models.

Are shorter timeframe predictions available?

Yes, we offer predictions for strategy purposes with shorter intervals including 1 minute, 2 minutes, 5 minutes, 15 minutes, and 30 minutes timeframes.

Should I use this for financial decisions?

Our ML model is designed for educational purposes only and should not be used as the sole basis for financial decisions. Always consult with a qualified financial advisor before making any investment decisions.

Share on Social Networks: